The IASP classification of chronic pain for ICD-11: chronic neuropathic pain
Abstract
The upcoming 11th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD) of the World Health Organization (WHO) offers a unique opportunity to improve the representation of painful disorders. For this purpose, the International Association for the Study of Pain (IASP) has convened an interdisciplinary task force of pain specialists. Here, we present the case for a reclassification of nervous system lesions or diseases associated with persistent or recurrent pain for ≥3 months. The new classification lists the most common conditions of peripheral neuropathic pain: trigeminal neuralgia, peripheral nerve injury, painful polyneuropathy, postherpetic neuralgia, and painful radiculopathy. Conditions of central neuropathic pain include pain caused by spinal cord or brain injury, poststroke pain, and pain associated with multiple sclerosis. Diseases not explicitly mentioned in the classification are captured in residual categories of ICD-11. Conditions of chronic neuropathic pain are either insufficiently defined or missing in the current version of the ICD, despite their prevalence and clinical importance. We provide the short definitions of diagnostic entities for which we submitted more detailed content models to the WHO. Definitions and content models were established in collaboration with the Classification Committee of the IASP's Neuropathic Pain Special Interest Group (NeuPSIG). Up to 10% of the general population experience neuropathic pain. The majority of these patients do not receive satisfactory relief with existing treatments. A precise classification of chronic neuropathic pain in ICD-11 is necessary to document this public health need and the therapeutic challenges related to chronic neuropathic pain.
MeSH terms
Funding
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Université Catholique de Louvain
- Aarhus Universitet
- Aarhus Universitetshospital
- Johns Hopkins University
- Helsinn
- University of Dundee
- Philipps-Universität Marburg
- Queen Mary University of London
- Les Laboratories Pierre Fabre
- European Federation of Pharmaceutical Industries and Associations
- Galápagos
- Glenmark Pharmaceuticals
- University of Cambridge
- Imperial College London
- King's College London
- University of Leeds
- European Commission
- Deutsche Forschungsgemeinschaft
- Institut National de la Santé et de la Recherche Médicale
- University of New South Wales
- Universiteit Maastricht
- Bundesministerium für Bildung und Forschung
- University of Toronto
- Eisai
- Karolinska Institutet
- Astellas Pharma
- Universitetet i Oslo
- National Yang-Ming University
- Université Paris Descartes
- Innovative Medicines Initiative
- Taipei Veterans General Hospital
- H. Lundbeck A/S
- Seqirus
- Genentech
- Allergan
- Department of Psychiatry, Columbia University
- Sanofi Pasteur
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine
- Barts and The London School of Medicine and Dentistry
- Brain Research Center, National Yang-Ming University
- Daiichi Sankyo Europe
How this paper connects to the literature. Drag to explore, click any node to open that paper.
